Genmab/$GMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Ticker
$GMAB
Sector
Health
Primary listing
Employees
2,638
Headquarters
Copenhagen, Denmark
Website
Genmab Metrics
BasicAdvanced
$14B
1.24
$18.36
0.80
-
Price and volume
Market cap
$14B
Beta
0.8
52-week high
$27.94
52-week low
$17.24
Average daily volume
1.1M
Financial strength
Current ratio
5.34
Quick ratio
5.324
Long term debt to equity
2.436
Total debt to equity
2.7
Interest coverage (TTM)
59.70%
Profitability
EBITDA (TTM)
1,144.737
Gross margin (TTM)
95.12%
Net profit margin (TTM)
35.27%
Operating margin (TTM)
33.97%
Effective tax rate (TTM)
13.85%
Revenue per employee (TTM)
$1,220,000
Management effectiveness
Return on assets (TTM)
11.54%
Return on equity (TTM)
22.80%
Valuation
Price to earnings (TTM)
1.236
Price to revenue (TTM)
0.436
Price to book
17.3
Price to tangible book (TTM)
28.77
Price to free cash flow (TTM)
1.252
Free cash flow yield (TTM)
79.87%
Free cash flow per share (TTM)
18.121
Growth
Revenue change (TTM)
25.43%
Earnings per share change (TTM)
276.80%
3-year revenue growth (CAGR)
35.22%
10-year revenue growth (CAGR)
41.16%
3-year earnings per share growth (CAGR)
52.13%
10-year earnings per share growth (CAGR)
33.18%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Genmab News
AllArticlesVideos
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Benzinga·4 days ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·2 weeks ago
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $14B as of August 12, 2025.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 1.24 as of August 12, 2025.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of August 12, 2025.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.